The treatment of Blood Builder & Cancer Risk Reduction with vitamins

Blood Builder and Cancer Risk Reduction: Mitamins custom make quality formulas for the treatment of Blood Builder & Cancer Risk Reduction with vitamins. A Blood Builder & Cancer Risk Reduction formula will be made to suit you, using quality brand name ingredients. Mitamins produce custom made vitamin and supplement formulas to suit your individual health needs conveniently in one formula, one bottle and one dosage. For assistance, call toll free: 1-866-585-1390
Your Supplements Facts - Covers the formulas above
Supplement Facts

Specially Formulated for: Blood Builder and Cancer Risk Reduction

  • Amount Per Serving
    % DV
    Vitamin A
    2500
    IU
    50%
    Vitamin C
    100
    mg
    167%
    Vitamin E
    100
    IU
    333%
    Folate
    400
    mcg
    100%
    Vitamin B12
    50
    mcg
    833%
    Iron
    9
    mg
    50%
    CoQ-10
    15
    mg
    *
  • Amount Per Serving
    % DV
    Grape Seed Extract
    50
    mg
    *
    Green Tea Extract
    50
    mg
    *
    L-Glutathione Reduced
    100
    mg
    *
    Yellow Dock Extract
    100
    mg
    *
    Dandelion Extract
    100
    mg
    *
    * Daily Value (DV) not established
Name Your Supplement Bottle - Just how you like it
The current default name is: 
 
(Click in box to change)
Your Perfect Supplement - Custom-made just for you
Formulas form 35 Years of Medical Practice
Blood Builder and Cancer Risk Reduction
Monthly Cost: $30.03
Serving Size:4-5
30 Days Money Back Guarantee
100% Satisfaction Guarantee

Blood Builder and Cancer Risk Reduction Formulas Details

Customize Your Supplements - Check all that apply
4A Select additional condition(s) you want to address:


4B Select all the medication(s) you are taking:
Update This Formula
If your concern or medication is not listed here, use our Formulator, which covers 680 concerns and 1600 drugs, Click here!
Latest Health Related News:
Survival Data In FDA Approval For ERBITUX(R) (Cetuximab) Supports Use As A Single Agent In Patients With Advanced Colorectal Cancer
ImClone Systems Incorporated (Nasdaq: IMCL) and Bristol-Myers Squibb Company (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) has approved an update to the ERBITUX(R) (Cetuximab) product labeling to include overall survival data as a single agent in epidermal growth factor inhibitor (EGFR)-expressing metastatic colorectal cancer (mCRC) patients after failure of both irinotecan- and oxaliplatin-based regimens.
Probiotics To Treat Diarrhea In Infants
Each year more than half a million infants worldwide, primarily in developing countries, die from diarrhoea caused by rotavirus. Even in industrialised countries management of the infection costs economies about $1 billion a year. Now a study in the online open access journal, BMC Microbiology demonstrates that with the addition of probiotic bacteria, preventative measures can potentially be made far cheaper but just as effective.
This information concerning the support of Blood Builder and Cancer Risk Reduction treatments provide basic knowledge which should always be discussed with your own health practitioner.
Any Questions, Call Us Toll Free: 1-866-585-1390
Mitamins Logo
Home  Multi-Conditions formulas  General Health  Blood Builder  Blood Builder and Cancer Risk Reduction
Live Chat System

manufactured In USA

  verisign          Trust E Finalmark

Custom Vitamins and Nutritional Supplements for Supporting Age-Related Cognitive Decline and Aging Treatments